Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. - sprookjes - yvandenbroek - TriplyDB

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q33425130

about

The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.

P2860

Q47601279-4A49BE76-C91B-4382-84B7-D4C874B50C45

P2860

Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer.

http://www.wikidata.org/entity/Q33425130

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Phase I dose escalation study ...... ed non-small cell lung cancer.

@ast

Phase I dose escalation study ...... ed non-small cell lung cancer.

@en

type

label

Phase I dose escalation study ...... ed non-small cell lung cancer.

@ast

Phase I dose escalation study ...... ed non-small cell lung cancer.

@en

prefLabel

Phase I dose escalation study ...... ed non-small cell lung cancer.

@ast

Phase I dose escalation study ...... ed non-small cell lung cancer.

@en

P1433

Q33425130-FDCF8543-883D-480C-ABDF-A4D4492EE779

P1476

Q33425130-421B4D2C-C18E-4589-9466-92474DF7CD88

P2093

Q33425130-209C304A-706D-4A95-9726-83AB0AC35194

Q33425130-2C4A4FE9-4CBF-4F39-9716-1A8FC101F5A6

Q33425130-4022921D-373E-4E04-A070-1F9C01E64D4A

Q33425130-43E9EC96-940E-4390-A587-FEEE5BEB08BA

Q33425130-648AB763-17E2-4AE0-8F72-C3878E7D7E23

Q33425130-8F04832C-27F3-4BD5-A0BA-467D04363C52

Q33425130-990E715F-9891-4393-B108-B4ED596C964F

Q33425130-B1989592-C1BB-4A85-8C97-3B1397746488

Q33425130-D71A4CD1-FBDB-44CB-8D56-0F5BB6E526C4

Q33425130-EFBC4ACB-8152-470C-AA14-D80752D39DC2

P2860

Q33425130-23B4D669-3FD5-4A83-9E09-571EF45E422A

Q33425130-27365B3A-C65A-4846-9C50-153A7252A1C6

Q33425130-321C92B8-94FE-4648-B42E-9B84DAF49C75

Q33425130-6A32C774-F789-4369-82FA-E3CD5AEE2FEC

Q33425130-A212CDEA-A16E-4FF0-B24B-D82AB7C3BD79

Q33425130-A28A1A39-41B5-45DF-9743-D658835C93AA

Q33425130-ACD076F7-AFF7-4B9D-8E1D-0A8D8689DFEA

Q33425130-AFDE532A-0F98-461C-80E6-BF57BA174BF2

Q33425130-B4FCE4E6-3BE3-40A0-934E-6B73E3E7D882

Q33425130-BF8D6FE0-DE79-45E8-B82D-0AA86C729485

P2888

Q33425130-00D3061A-065C-44BD-8364-2CA19B965E48

P304

Q33425130-16BEB51B-4CF6-43CC-9FE8-F8BF2DDDF580

P31

Q33425130-D1053F9E-0479-42EA-B645-87BA5F272067

P356

Q33425130-023D9612-1BBE-4102-9324-0666DC0735CC

P433

Q33425130-4CF81204-322D-414E-8E12-0FF16BEEB6AF

P478

Q33425130-B65227C7-1A13-4056-918D-590FB5A41861

P50

Q33425130-59E74C95-38D9-442B-A772-9E348893A4CE

P577

Q33425130-1500CED3-D213-4C76-B266-E5064C3FD170

P698

Q33425130-D93EB7E3-E99C-49CE-9336-E00E23B590B5

P356

S10147-015-0883-7

P1433

International Journal of Clinical Oncology

P1476

Phase I dose escalation study ...... ed non-small cell lung cancer.

@en

P2093

Akihiro Ono

http://www.w3.org/2001/XMLSchema#string

Hisao Imai

http://www.w3.org/2001/XMLSchema#string

Kyoichi Kaira

http://www.w3.org/2001/XMLSchema#string

Masanobu Yamada

http://www.w3.org/2001/XMLSchema#string

Noriaki Sunaga

http://www.w3.org/2001/XMLSchema#string

Takeshi Hisada

http://www.w3.org/2001/XMLSchema#string

Tamotsu Ishizuka

http://www.w3.org/2001/XMLSchema#string

Tomohito Kuwako

http://www.w3.org/2001/XMLSchema#string

Tomomi Masuda

http://www.w3.org/2001/XMLSchema#string

Yosuke Kamide

http://www.w3.org/2001/XMLSchema#string

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Amrubicin for non-small-cell lung cancer and small-cell lung cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.

Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.

P2888

s10147-015-0883-7

P304

240-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-015-0883-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26266640

http://www.w3.org/2001/XMLSchema#string